Nonalcoholic Steatohepatitis Nash
Mostrando 1-12 de 26 artigos, teses e dissertações.
-
1. Trajectory of NAFLD characteristics after Roux-en-Y gastric bypass: a five-year historical cohort study
Abstract BACKGROUND: The long-term effects of bariatric surgery on the course of non-alcoholic fatty hepatopathy (NAFLD) are not fully understood. OBJECTIVE: To analyze the evolution of NAFLD characteristics through noninvasive markers after Roux-en-Y gastric bypass (RYGB) over a five-year period. DESIGN AND SETTING: Historical cohort study; tertiary-leve
Sao Paulo Medical Journal. Publicado em: 2022
-
2. EVALUATION OF PROGRESSION OF HEPATIC FIBROSIS IN A GROUP OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANIED FOR 10 YEARS
RESUMO CONTEXTO: A doença hepática gordurosa não alcoólica vem sendo diagnosticada com frequência progressivamente maior na população geral, como consequência do aumento da prevalência da obesidade e do diabetes mellitus tipo 2, considerados seus principais fatores de risco. Caracteriza-se por acúmulo de gordura nos hepatócitos associada à infl
Arq. Gastroenterol.. Publicado em: 30/09/2019
-
3. N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL
RESUMO CONTEXTO: Atualmente, o tratamento farmacológico da doença hepática gordurosa não alcoólica (DHGNA) ainda é limitado e baseia-se no tratamento de condições associadas às comorbidades. O estresse oxidativo e a resistência à insulina são os mecanismos que parecem estar mais envolvidos em sua patogênese. OBJETIVO: Avaliar a eficácia da
Arq. Gastroenterol.. Publicado em: 26/08/2019
-
4. [RETRACTED ARTICLE] Characteristics of liver fibrosis with different etiologies using a fully quantitative fibrosis assessment tool
This study aimed to test the diagnostic performance of a fully quantitative fibrosis assessment tool for liver fibrosis in patients with chronic hepatitis B (CHB), primary biliary cirrhosis (PBC) and non-alcoholic steatohepatitis (NASH). A total of 117 patients with liver fibrosis were included in this study, including 50 patients with CHB, 49 patients with
Braz J Med Biol Res. Publicado em: 18/05/2017
-
5. Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
Liver fibrosis occurring as an outcome of non-alcoholic steatohepatitis (NASH) can precede the development of cirrhosis. We investigated the effects of sorafenib in preventing liver fibrosis in a rodent model of NASH. Adult Sprague-Dawley rats were fed a choline-deficient high-fat diet and exposed to diethylnitrosamine for 6 weeks. The NASH group (n=10) rece
Braz J Med Biol Res. Publicado em: 24/02/2015
-
6. Efeito dos ácidos graxos saturados, poli-insaturados e trans no desenvolvimento de aterosclerose e esteatose hepática em camundongos com ablação gênica do receptor de LDL / Effect of saturated, polyunsaturated and trans fatty acids on the development of atherosclerosis and hepatic steatosis of mice with ablation of the LDL receptor gene
Introduction: The amount and type of dietary fat play important roles on the development of cardiovascular disease (CVD) and on the development of hepatic steatosis. Saturated (SAT) and trans (TRANS) fatty acids are known as pro-atherogenic, while the polyunsaturated (POLY) fats seem to exert an antiatherogenic action. Regarding hepatic steatosis, it is know
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 18/12/2012
-
7. Alopurinol na prevenção da esteato-hepatite não alcoólica e hiperglicemia induzida por dieta rica em frutose em ratos wistar
Nonalcoholic fatty liver disease (NAFLD) in the last two decades has been recognized as the most common chronic liver disease in Western countries, paralleling the epidemic of obesity and consumption of high-fructose diet. Researchers suggest that NAFLD may be the hepatic manifestation of metabolic syndrome. Although NAFLD and hyperuricemia are strongly rela
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 27/03/2012
-
8. Ação hepatoprotetora do antioxidante quercitina no modelo esperimental de esteato-hepatite não alcoólica
Introduction: Non-alcoholic steatohepatitis is a disease with a high incidence, difficult diagnosis, and yet no effective treatment. This reasons lead to the use of experimental models for induction of NASH, and the study of routes developing this disease, as well as attempts to a effective therapy. Aims: This study was designed to develop an experimental mo
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 2012
-
9. Consumo Alimentar dos Portadores de Doença Hepática Gordurosa Não Alcoólica: Comparação entre a Presença e Ausência de Síndrome Metabólica e a Gravidade da Doença / Food Intake of Patients with Nonalcoholic Fatty Liver Disease: Comparison between the presence and absence of Metabolic Syndrome and Severity of Disease
Purpose: To evaluate the dietary intake of subjects with nonalcoholic fatty liver disease (NAFLD) and compare with recommended dietary intake, presence and absence of metabolic syndrome (MS) and disease severity (presence and absence of nonalcoholic steatohepatitis). Methods: We first evaluated 158 patients with a diagnosis of NAFLD by clinical examination,
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 25/05/2011
-
10. Esteato-hepatite não alcoólica e esteatose em hepatite crônica pelo vírus C: prevalência e relações entre dados demográficos e clínico-laboratoriais com parâmetros histopatológicos / Nonalcoholic steatohepatitis and steatosis in chronic hepatitis C: prevalence and the relationship between demographic, clinical and laboratory data with histopathological parameters
Chronic hepatitis C is the leading cause of progressive liver damage and related complications, such as cirrhosis and primary hepatocellular carcinoma. Fibrosis stage and necro-inflammatory activity grade are good predictors of disease progression in chronic hepatitis C (CHC).The global epidemic of obesity and diabetes are associated with the increasing inci
Publicado em: 2010
-
11. Evaluation of Yo Jyo Hen Shi Ko (YHK) in hepatic lipid metabolism in experimental steatohepatitis / Efeito do Yo Jyo Hen Shi Ko (YHK) no metabolismo lipídico na esteatohepatite experimental
A Doença Hepática Gordurosa Não Alcoólica (DHGNA) é atualmente uma das formas mais comuns de doença hepática, e está diretamente relacionada com a obesidade. Estudos indicam uma prevalência por volta de 30% na população ocidental e 11% na população oriental. A DGHNA possui um largo espectro abrangendo desde casos de esteatose simples sem inflama
Publicado em: 2010
-
12. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?
Non-alcoholic steatohepatitis (NASH) has been associated with hepatocellular carcinoma (HCC) often arising in histologically advanced disease when steatohepatitis is not active (cryptogenic cirrhosis). Our objective was to characterize patients with HCC and active, histologically defined steatohepatitis. Among 394 patients with HCC detected by ultrasound ima
Brazilian Journal of Medical and Biological Research. Publicado em: 04/09/2009